U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end? 

The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.

He’s picking Nicole B. Saphier, MD, a board-certified breast specialist with Memorial Sloan Kettering Cancer Center and Fox News contributor, to fill the key role.